A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes
CA059-001
Phase 1 other active
Quick answer
A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes for Acute Myeloid Leukemia and Myelodysplastic Syndromes is a Phase 1 program (other) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Phase
- Phase 1
- Modality
- other
- Status
- active